The FDA has cautioned that high doses of Zocor, commercially sold as simvastatin, bears an amplified risk of muscle injury.

The FDA has also issued a warning that mixing Zocor with particular drugs also increases the risk of muscle injury. It can lead to an exceptional but grave complication known as rhabdomyolysis. Rhabdomyolysis may occasionally result in fatal renal damage.

The combination drugs Vytorin and Simcor also contain simvastatin, in which the active element is Zocor. Zocor belongs to a class of drugs called statins. All statin drugs hold a danger of muscle damage, but new data proposes that this threat is predominantly towering for the 80 milligram dose of Zocor.

Dr. Eric Colman, Deputy Director of FDA's Division of Metabolism and Endocrinology Products, evinced, "It's important for patients and healthcare professionals to consider all the potential risks and known benefits of any drug before deciding on any one therapy or dose of therapy".

The warning ensues after an FDA review of fresh data on the hazard of muscle injury from clinical trials.

The FDA also claimed that it was appraising data from a clinical trial which observed cardiovascular disease in patients who were prescribed 80 mg of simvastatin in contrast to those on 20 mg.